Protagonist Therapeutics Inc
NASDAQ:PTGX
Income Statement
Earnings Waterfall
Protagonist Therapeutics Inc
Income Statement
Protagonist Therapeutics Inc
| Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
9
N/A
|
20
+128%
|
31
+54%
|
43
+38%
|
40
-6%
|
31
-22%
|
22
-30%
|
2
-92%
|
(0)
N/A
|
0
N/A
|
2
+909%
|
17
+621%
|
26
+54%
|
29
+11%
|
31
+9%
|
27
-13%
|
24
-10%
|
27
+12%
|
47
+71%
|
45
-3%
|
35
-23%
|
27
-24%
|
1
-97%
|
0
N/A
|
0
N/A
|
60
N/A
|
315
+425%
|
319
+1%
|
324
+1%
|
434
+34%
|
208
-52%
|
209
+1%
|
209
+0%
|
46
-78%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(15)
|
(19)
|
(23)
|
(26)
|
(33)
|
(40)
|
(48)
|
(55)
|
(58)
|
(63)
|
(68)
|
(70)
|
(73)
|
(70)
|
(73)
|
(79)
|
(81)
|
(88)
|
(89)
|
(89)
|
(93)
|
(101)
|
(109)
|
(132)
|
(153)
|
(170)
|
(179)
|
(167)
|
(158)
|
(147)
|
(147)
|
(153)
|
(154)
|
(166)
|
(167)
|
(175)
|
(182)
|
(181)
|
(185)
|
(190)
|
(204)
|
|
| Selling, General & Administrative |
(3)
|
(4)
|
(4)
|
(5)
|
(7)
|
(9)
|
(10)
|
(11)
|
(12)
|
(12)
|
(12)
|
(13)
|
(14)
|
(14)
|
(15)
|
(15)
|
(16)
|
(17)
|
(17)
|
(18)
|
(19)
|
(20)
|
(23)
|
(25)
|
(27)
|
(32)
|
(33)
|
(32)
|
(32)
|
(30)
|
(31)
|
(32)
|
(33)
|
(40)
|
(40)
|
(43)
|
(43)
|
(40)
|
(41)
|
(42)
|
(45)
|
|
| Research & Development |
(12)
|
(15)
|
(19)
|
(21)
|
(26)
|
(31)
|
(38)
|
(43)
|
(46)
|
(50)
|
(56)
|
(57)
|
(60)
|
(57)
|
(58)
|
(63)
|
(65)
|
(71)
|
(72)
|
(71)
|
(75)
|
(80)
|
(86)
|
(107)
|
(126)
|
(138)
|
(146)
|
(135)
|
(126)
|
(117)
|
(116)
|
(121)
|
(120)
|
(126)
|
(127)
|
(132)
|
(138)
|
(140)
|
(144)
|
(148)
|
(159)
|
|
| Operating Income |
(15)
N/A
|
(19)
-29%
|
(23)
-21%
|
(26)
-13%
|
(33)
-24%
|
(40)
-22%
|
(48)
-20%
|
(46)
+5%
|
(38)
+17%
|
(32)
+16%
|
(26)
+18%
|
(30)
-17%
|
(42)
-39%
|
(49)
-15%
|
(71)
-46%
|
(79)
-11%
|
(81)
-2%
|
(86)
-6%
|
(72)
+15%
|
(63)
+13%
|
(65)
-2%
|
(69)
-8%
|
(82)
-17%
|
(108)
-32%
|
(126)
-17%
|
(123)
+2%
|
(134)
-9%
|
(132)
+1%
|
(131)
+0%
|
(146)
-11%
|
(147)
-1%
|
(153)
-4%
|
(94)
+39%
|
149
N/A
|
152
+2%
|
149
-2%
|
253
+70%
|
27
-89%
|
24
-12%
|
19
-21%
|
(158)
N/A
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
(0)
|
(5)
|
(5)
|
(5)
|
(4)
|
0
|
1
|
1
|
1
|
1
|
2
|
2
|
3
|
3
|
3
|
3
|
3
|
2
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
4
|
6
|
10
|
13
|
15
|
17
|
20
|
24
|
26
|
30
|
30
|
29
|
29
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(15)
N/A
|
(24)
-61%
|
(28)
-16%
|
(31)
-13%
|
(37)
-18%
|
(40)
-6%
|
(47)
-20%
|
(45)
+5%
|
(37)
+18%
|
(31)
+17%
|
(24)
+21%
|
(28)
-16%
|
(40)
-41%
|
(46)
-16%
|
(68)
-48%
|
(76)
-11%
|
(78)
-3%
|
(84)
-8%
|
(71)
+15%
|
(63)
+12%
|
(65)
-4%
|
(69)
-6%
|
(81)
-18%
|
(108)
-32%
|
(126)
-17%
|
(122)
+2%
|
(133)
-8%
|
(130)
+2%
|
(127)
+2%
|
(140)
-10%
|
(138)
+2%
|
(140)
-2%
|
(79)
+44%
|
165
N/A
|
173
+4%
|
173
+0%
|
279
+61%
|
57
-80%
|
54
-6%
|
48
-11%
|
(129)
N/A
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
1
|
1
|
(2)
|
(2)
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(3)
|
(2)
|
(4)
|
(1)
|
(2)
|
(2)
|
(1)
|
|
| Income from Continuing Operations |
(15)
|
(24)
|
(28)
|
(31)
|
(37)
|
(40)
|
(47)
|
(45)
|
(37)
|
(31)
|
(24)
|
(28)
|
(39)
|
(45)
|
(66)
|
(74)
|
(77)
|
(83)
|
(73)
|
(65)
|
(66)
|
(70)
|
(81)
|
(108)
|
(126)
|
(122)
|
(133)
|
(130)
|
(127)
|
(140)
|
(138)
|
(140)
|
(79)
|
162
|
170
|
171
|
275
|
56
|
52
|
46
|
(130)
|
|
| Net Income (Common) |
(15)
N/A
|
(24)
-61%
|
(28)
-17%
|
(32)
-14%
|
(38)
-18%
|
(40)
-6%
|
(48)
-19%
|
(45)
+5%
|
(37)
+18%
|
(31)
+17%
|
(24)
+21%
|
(28)
-16%
|
(39)
-38%
|
(45)
-17%
|
(66)
-45%
|
(74)
-12%
|
(77)
-5%
|
(83)
-8%
|
(73)
+12%
|
(65)
+12%
|
(66)
-2%
|
(70)
-6%
|
(81)
-16%
|
(108)
-32%
|
(126)
-17%
|
(122)
+2%
|
(133)
-8%
|
(130)
+2%
|
(127)
+2%
|
(140)
-10%
|
(138)
+2%
|
(140)
-2%
|
(79)
+44%
|
162
N/A
|
170
+5%
|
171
+1%
|
275
+61%
|
56
-80%
|
52
-7%
|
46
-12%
|
(130)
N/A
|
|
| EPS (Diluted) |
-1.02
N/A
|
-1.64
-61%
|
-1.92
-17%
|
-2.18
-14%
|
-2.57
-18%
|
-2.38
+7%
|
-2.82
-18%
|
-2.67
+5%
|
-2.09
+22%
|
-1.44
+31%
|
-1.14
+21%
|
-1.22
-7%
|
-1.74
-43%
|
-1.86
-7%
|
-2.67
-44%
|
-2.72
-2%
|
-2.98
-10%
|
-3
-1%
|
-2.23
+26%
|
-1.73
+22%
|
-1.92
-11%
|
-1.58
+18%
|
-1.81
-15%
|
-2.24
-24%
|
-2.71
-21%
|
-2.51
+7%
|
-2.7
-8%
|
-2.64
+2%
|
-2.6
+2%
|
-2.77
-7%
|
-2.42
+13%
|
-2.37
+2%
|
-1.39
+41%
|
2.54
N/A
|
2.77
+9%
|
2.76
0%
|
4.23
+53%
|
0.89
-79%
|
0.81
-9%
|
0.71
-12%
|
-2.05
N/A
|
|